Evaluation and strategies to generate mucosal antibodies against HIV-1 infection

Mucosal HIV infection is currently the leading cause of the global AIDS epidemic, with most infections occurring through sexual intercourse. A truly effective vaccine capable of protecting vaccines from HIV acquisition will likely require mucosal mediated immune protection. Previous non-human primat...

Full description

Bibliographic Details
Main Author: Klein, Katja
Published: St George's, University of London 2012
Subjects:
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.568768
id ndltd-bl.uk-oai-ethos.bl.uk-568768
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-5687682015-03-20T05:10:03ZEvaluation and strategies to generate mucosal antibodies against HIV-1 infectionKlein, Katja2012Mucosal HIV infection is currently the leading cause of the global AIDS epidemic, with most infections occurring through sexual intercourse. A truly effective vaccine capable of protecting vaccines from HIV acquisition will likely require mucosal mediated immune protection. Previous non-human primate studies have provided the proof of concept that neutralising antibodies can prevent infection, however the levels of antibody at mucosal surfaces required for protection have not been fully characterised. Furthermore, to date no effective vaccination strategy has been shown to efficiently induce protective mucosal humoral responses. In spite of this, recent evidence suggests that directly targeting vaccines towards mucosal surfaces may enhance local immune responses. Thus this thesis has two hypotheses. First to determine the levels of mucosal antibody required to provide sterilising protection in the macaque model. Second using the murine model to develop strategies to enhance vaccine antigen delivery across mucosal surfaces, as an approach to induce mucosal humoral immune responses. We demonstrate that the presence of neutralising 2F5 IgG antibody at the time of vaginal challenge is able to give sterilising protection in the macaque model, and that the whole IgG molecule was essential for protection, while the Fab' portion was inefficient. Furthermore we show that permeation enhancer can play an important role in the delivery of vaccine antigens across mucosal surfaces, where the vaginal route of immunisation is the least effective one. In summary, we present supporting data for the role of humoral immune responses in protection against HIV infection and ways in which to increase the bioavailability of mucosally applied antigens to initiate the development of mucosal antibodies616.979201St George's, University of Londonhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.568768Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 616.979201
spellingShingle 616.979201
Klein, Katja
Evaluation and strategies to generate mucosal antibodies against HIV-1 infection
description Mucosal HIV infection is currently the leading cause of the global AIDS epidemic, with most infections occurring through sexual intercourse. A truly effective vaccine capable of protecting vaccines from HIV acquisition will likely require mucosal mediated immune protection. Previous non-human primate studies have provided the proof of concept that neutralising antibodies can prevent infection, however the levels of antibody at mucosal surfaces required for protection have not been fully characterised. Furthermore, to date no effective vaccination strategy has been shown to efficiently induce protective mucosal humoral responses. In spite of this, recent evidence suggests that directly targeting vaccines towards mucosal surfaces may enhance local immune responses. Thus this thesis has two hypotheses. First to determine the levels of mucosal antibody required to provide sterilising protection in the macaque model. Second using the murine model to develop strategies to enhance vaccine antigen delivery across mucosal surfaces, as an approach to induce mucosal humoral immune responses. We demonstrate that the presence of neutralising 2F5 IgG antibody at the time of vaginal challenge is able to give sterilising protection in the macaque model, and that the whole IgG molecule was essential for protection, while the Fab' portion was inefficient. Furthermore we show that permeation enhancer can play an important role in the delivery of vaccine antigens across mucosal surfaces, where the vaginal route of immunisation is the least effective one. In summary, we present supporting data for the role of humoral immune responses in protection against HIV infection and ways in which to increase the bioavailability of mucosally applied antigens to initiate the development of mucosal antibodies
author Klein, Katja
author_facet Klein, Katja
author_sort Klein, Katja
title Evaluation and strategies to generate mucosal antibodies against HIV-1 infection
title_short Evaluation and strategies to generate mucosal antibodies against HIV-1 infection
title_full Evaluation and strategies to generate mucosal antibodies against HIV-1 infection
title_fullStr Evaluation and strategies to generate mucosal antibodies against HIV-1 infection
title_full_unstemmed Evaluation and strategies to generate mucosal antibodies against HIV-1 infection
title_sort evaluation and strategies to generate mucosal antibodies against hiv-1 infection
publisher St George's, University of London
publishDate 2012
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.568768
work_keys_str_mv AT kleinkatja evaluationandstrategiestogeneratemucosalantibodiesagainsthiv1infection
_version_ 1716789302760833024